ProQR Therapeutics NV (NASDAQ: PRQR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating.
ProQR Therapeutics N.V. - Ordinary Shares (PRQR)
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
proqr.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
PRQR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRQR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRQR alerts
High impacting ProQR Therapeutics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRQR
News
- ProQR Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- ProQR Announces Third Quarter 2024 Operating and Financial ResultsGlobeNewswire
- ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $14.00 price target on the stock, up previously from $6.00.MarketBeat
- ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement [Yahoo! Finance]Yahoo! Finance
- ProQR Announces Closing of Underwritten Public Offering and Concurrent Private PlacementGlobeNewswire
PRQR
Earnings
- 11/7/24 - Beat
PRQR
Sec Filings
- 11/7/24 - Form 6-K
- 10/25/24 - Form 6-K
- 10/24/24 - Form 424B5
- PRQR's page on the SEC website